New Scientific Publication Featuring SHIKARI® Bevacizumab ELISA Kits

We are pleased to share that SHIKARI® (Q-BEVA) Bevacizumab ELISA and SHIKARI® (S-ATB) Anti-Bevacizumab ELISA kits have been featured in a newly published peer-reviewed scientific study, demonstrating their application in biomarker research for patients receiving bevacizumab therapy.

The publication, "Predictive Biomarkers in Metastatic Colorectal Cancer Patients Treated With Bevacizumab: A Turkish Oncology Group (TOG) Study," investigated potential biomarkers associated with treatment response in metastatic colorectal cancer (mCRC) patients receiving bevacizumab-based therapy.

We are proud to see SHIKARI® assays supporting high-quality clinical research and would like to thank the investigators of the Turkish Oncology Group (TOG) for their confidence in our products.

Product pages:
SHIKARI® (Q-BEVA) Bevacizumab ELISA
SHIKARI® (S-ATB) Anti-Bevacizumab ELISA

Read the publication:
https://onlinelibrary.wiley.com/doi/10.1002/ijc.70588